Algeldrate
ALIMENTARY TRACT AND METABOLISM
Also known as: aluminium hydroxide, aluminum hydroxide, aluminum hydroxide hydrate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Algeldrate is a drug catalogued in DrugCentral. It was first approved by the FDA in 1983. Recorded indications include Duodenal ulcer disease, Gastric Hypersecretory Conditions, Gastric ulcer and Gastroesophageal reflux disease.
- Indications: Duodenal ulcer disease, Gastric Hypersecretory Conditions, Gastric ulcer, Gastroesophageal reflux disease and Heartburn and others.
- ATC code: A02AB01 (Aluminium compounds).
- Molecular formula: AlH3O3; molecular weight 78.00 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (7)
- Duodenal ulcer disease
- Gastric Hypersecretory Conditions
- Gastric ulcer
- Gastroesophageal reflux disease
- Heartburn
- Indigestion
- Peptic ulcer
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1983-12-09 | FDA | — | SANOFI AVENTIS US |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A02AB01 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › ANTACIDS › Aluminium compounds |
A02AB02 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › ANTACIDS › Aluminium compounds |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Schizoaffective disorder | 709.1 |
| Drug level increased | 398.4 |
| Electrocardiogram QT prolonged | 318.3 |
| Drug interaction | 151.6 |
| Sinus rhythm | 118.8 |
| Appendicolith | 108.6 |
| Hyperphosphataemia | 101.8 |
| Myasthenia gravis | 91.5 |
| Blood phosphorus increased | 88.2 |
| Appendicitis | 85.8 |
| Blood uric acid increased | 82.1 |
| Ventricular fibrillation | 76.7 |
Chemical structure
| Molecular formula | AlH3O3 |
|---|---|
| Molecular weight | 78.00 g/mol |
| CAS number | 21645-51-2 |
| InChIKey | WNROFYMDJYEPJX-UHFFFAOYSA-K |
| PubChem CID | 22721319 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Algeldrate used for?
DrugCentral lists the following indications for Algeldrate: Duodenal ulcer disease, Gastric Hypersecretory Conditions, Gastric ulcer, Gastroesophageal reflux disease, Heartburn, Indigestion and Peptic ulcer.
When was Algeldrate first approved?
Algeldrate was first approved by the FDA in 1983.
What is the chemical formula of Algeldrate?
Algeldrate has the molecular formula AlH3O3 and a molecular weight of 78.00 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4250 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200706 — compound record and bioactivity
- PubChem CID 22721319 — chemical identifiers
- DrugBank DB06723 — drug record
- FDA UNII 03J11K103C — substance identity
- DailyMed: FDA labels for Algeldrate — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.